ActiPatch applied at Vagus Nerve for Canine Osteoa
Post# of 7798
(Total Views: 225)
Posted On: 03/25/2024 6:45:19 PM
ActiPatch applied at Vagus Nerve for Canine Osteoarthritis
Pulsed shortwave electromagnetic field therapy increases quality of life in canines with symptoms of osteoarthritics
22 March 2024
Veterinary Medicine and Science
Results
Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N = 26) were reduced from 3.74 to 2.10 (44%), compared to no improvement in the placebo group (N = 23) over the study period (p = 0.0001). Average PROM scores increased by 5.51 (4.59–6.23) degrees relative to the placebo group (p < 0.01). Ninety-six per cent of the treatment group showed either increased PROM or improved behavioural changes or both , compared to 4% for the placebo group (p < 0.01). Most changes occurred within the first 8 days of treatment.
The PSWT device used in this study was the model 088 medical device manufactured by BioElectronics Corporation, an over-the-counter product cleared by the US FDA for human use (Figure 1). This device uses a 5.5 cm flexible loop antenna (magnetic dipole). The device produces a pulsed, radio frequency magnetic field at 27.1 MHz, with a pulse width of 100 ms and a pulse repetition frequency of 1 kHz.
https://onlinelibrary.wiley.com/doi/10.1002/vms3.1408
Pulsed shortwave electromagnetic field therapy increases quality of life in canines with symptoms of osteoarthritics
22 March 2024
Veterinary Medicine and Science
Results
Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N = 26) were reduced from 3.74 to 2.10 (44%), compared to no improvement in the placebo group (N = 23) over the study period (p = 0.0001). Average PROM scores increased by 5.51 (4.59–6.23) degrees relative to the placebo group (p < 0.01). Ninety-six per cent of the treatment group showed either increased PROM or improved behavioural changes or both , compared to 4% for the placebo group (p < 0.01). Most changes occurred within the first 8 days of treatment.
The PSWT device used in this study was the model 088 medical device manufactured by BioElectronics Corporation, an over-the-counter product cleared by the US FDA for human use (Figure 1). This device uses a 5.5 cm flexible loop antenna (magnetic dipole). The device produces a pulsed, radio frequency magnetic field at 27.1 MHz, with a pulse width of 100 ms and a pulse repetition frequency of 1 kHz.
https://onlinelibrary.wiley.com/doi/10.1002/vms3.1408
(2)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼